Abstract 2342
Background
The FIRSTANA trial compared docetaxel 75mg/m2 Q3W (D75), cabazitaxel 20mg/m2 Q3W (C20) and cabazitaxel 25mg/m2 Q3W (C25) in patients with chemo-naive mCRPC (Oudard 2017). FIRSTANA enrolled patients regardless of presence of disease-related symptoms. This post-hoc analysis of FIRSTANA evaluates the influence of progression type on outcomes.
Methods
Patient outcomes (OS, PSA response [confirmed PSA decline from baseline ≥ 50%] and radiological PFS [rPFS]) were analyzed according to progression type at randomization. Progression at randomization was defined as follows: PSA progression only (PSA-p) with no radiological progression (Radio-p) and no pain, Radio-p (± PSA-p, no pain), pain progression (mean Present Pain Intensity ≥2 and/or mean analgesic score ≥ 10 over the 7 days prior to randomization (±PSA-p, ±Radio-p).
Results
PSA-p, Radio-p and Pain-p were present in 34.4%, 23.2% and 42.3% of patients at randomization, respectively. Pain progression at initiation of chemotherapy was associated with features of aggressive disease and a shorter OS. Lower activity of C20 than C25 and D75 was observed in patients with Pain-p.Table:
859P
Progression type | ||||
---|---|---|---|---|
PSA-p N = 362 | Radio-p N = 244 | Pain-p N = 445 | Global p° | |
- PSA decrease ≥ 50% - Overall - D75 - C20 - C25 | 69.0% 67.4% 71.0% 69.0% | 69.8% 65.8% 66.2% 78.3% | 58.0% 62.2% 49.3% 63.0% | P = 0.003 P = 0.70 P = 0.002 P = 0.21 |
-rPFS, median [95% CI]* - Overall - D75 - C20 - C25 | 16.5 [14.3; 18.9] 13.5 [11.3; 16.7] 19.7 [14.3; 26.5] 18.2 [14.2; 22.6] | 12.1 [11.2; 14.4] 11.3 [9.7; 14.4] 13.4 [10.6; 22.8] 11.4 [10.1; 15.7] | 10.8 [9.3;11.6] 11.4 [8.8; 13.9] 9.1 [7.6; 10.9] 11.1 [9.7; 12.8] | p < 0.001 p = 0.13 p < 0.001 p = 0.001 |
OS, median [95% CI]* - Overall - D75 - C20 - C25 | 27.7 [25.4;31.2] 29.0 [22.6; 36.6] 30.0 [24.9; NR] 26.5 [24.0; 31.6] | 30.6 [26.8;34.3] 28.4 [22.0; 34.1] 32.1 [27.9; 41.4] 29.7 [24.0; 38.5] | 18.5 [16.8; 20.6] 20.3[16.5;24.3] 16.5[14.3; 19.1] 20.4[17.0;25.3] | p < 0.001 p = 0.003 p < 0.001 p = 0.031 |
in months, NR: not reached; °Log rank test for rPFS and OS, CMH test adjusted on stratification factors
Conclusions
Most patients in FIRSTANA had pain progression at randomization and this factor was associated with worse OS. In this post-hoc, subgroup analysis, C20 appeared less active than D75 and C25 in men with baseline pain progression.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Nicolas Delanoy.
Funding
Sanofi.
Disclosure
N. Delanoy: Travel / Accommodation / Expenses: Sanofi; Honoraria (self): Tesaro; Honoraria (self): MSD. D. Robbrecht: Travel / Accommodation / Expenses: Sanofi; Advisory / Consultancy: Bayer. K. Fizazi: Honoraria (self): Amgen; Honoraria (self): Astellas; Honoraria (self): AstraZeneca; Honoraria (self): Bayer; Honoraria (self): Clovis; Honoraria (self): CureVac; Honoraria (self): Essa; Honoraria (self): Genentech; Honoraria (self): Janssen; Honoraria (self): MSD; Honoraria (self): Orion; Honoraria (self): Sanofi. F. Mercier: Honoraria (self): Sanofi; Honoraria (self): AstraZeneca; Shareholder / Stockholder / Stock options, Stat Process is a CRO providing statistical services to various companies: Stat Process. O. Sartor: Shareholder / Stockholder / Stock options: Eli Lilly; Shareholder / Stockholder / Stock options: GlaxoSmithKline; Shareholder / Stockholder / Stock options: Noria; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Bayer; Advisory / Consultancy: Bellicum; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Johnson &Johnson; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Sanofi; Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy: Dendreon; Advisory / Consultancy, Research grant / Funding (institution): Endocyte; Advisory / Consultancy: Constellation Pharmaceuticals; Advisory / Consultancy: Advanced Accelerator Applications; Advisory / Consultancy: Pfizer; Advisory / Consultancy: BMS; Advisory / Consultancy: Celgene; Advisory / Consultancy: Bavarian Nordic; Advisory / Consultancy: Oncogenex; Advisory / Consultancy: EMD Serono; Advisory / Consultancy: Astellas; Advisory / Consultancy, Travel / Accommodation / Expenses: Progenics. R. de Wit: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Sanofi; Honoraria (self), Advisory / Consultancy: MSD; Honoraria (self), Advisory / Consultancy: Lilly; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Genentech. S. Oudard: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Sanofi; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Astellas; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Janssen; Honoraria (self): Bayer; Honoraria (self): Pfizer; Honoraria (self): MSD; Honoraria (self): Novartis; Honoraria (self): BMS; Honoraria (self): Ipsen.
Resources from the same session
3630 - Results of phase 1 clinical trial of high doses of Seleno-L-methionine (SLM) in sequential combination with Axitinib in previously treated and relapsed clear cell renal carcinoma (ccRCC) patients
Presenter: Yousef Zakharia
Session: Poster Display session 3
Resources:
Abstract
2356 - Safety and Efficacy of CDX-014 , an Antibody-Drug Conjugate against T Cell immunoglobulin mucin-1 (TIM-1), in advanced Renal Cell Carcinoma
Presenter: Bradley McGregor
Session: Poster Display session 3
Resources:
Abstract
1028 - SPAZO2 (SOGUG): Outcomes and prognostic significance of IMDC intermediate prognosis subclassification in metastatic renal cell carcinoma (mRCC) in patients treated with 1st-line pazopanib (1stPz).
Presenter: Begona P. Valderrama
Session: Poster Display session 3
Resources:
Abstract
2293 - Effect of Antacid Intake on the Therapeutic Efficacy of Sunitinib (SUN) in Metastatic Renal Cell Carcinoma (mRCC) Patients (pts): a Sub-Analysis of the STAR-TOR Registry
Presenter: Katrin Schlack
Session: Poster Display session 3
Resources:
Abstract
1451 - Randomized phase 3 trial of avelumab + axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN Renal 101 Japanese subgroup analysis
Presenter: Motohide Uemura
Session: Poster Display session 3
Resources:
Abstract
4399 - Overall and progression-free survival according to MSKCC scores in 1st line sunitinib treatment of metastatic renal cell carcinoma (mRCC)
Presenter: Jindrich Finek
Session: Poster Display session 3
Resources:
Abstract
1344 - Combination therapy with checkpoint inhibitors for first-line treatment of advanced renal cell carcinoma: A systematic review and meta-analysis of randomized controlled trials
Presenter: Kyaw Thein
Session: Poster Display session 3
Resources:
Abstract
3462 - A phase II trial of TKI induction followed by a randomized comparison between nivolumab or TKI continuation in renal cell carcinoma (NIVOSWITCH)
Presenter: Viktor Grünwald
Session: Poster Display session 3
Resources:
Abstract
5268 - Nivolumab (N) treatment beyond progression in a real-world cohort of patients (pts) with metastatic renal cell carcinoma (mRCC)
Presenter: Sophie Hans
Session: Poster Display session 3
Resources:
Abstract
4235 - First results of safety profile of nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC) in NIVES Study
Presenter: Cristina Masini
Session: Poster Display session 3
Resources:
Abstract